Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (601-610 of 962) with videos related to

Pageof 97
Sort By:
Journal of the American Heart Association|October 30, 2018
Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH ModelLotte Kaasenbrood, Deepak L Bhatt, Jannick A N Dorresteijn, et al.
Journal of the American Heart Association|October 7, 2022
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical IllnessGary E Raskob, Walter Ageno, Gregory Albers, et al.
European Journal of Preventive Cardiology|February 8, 2025
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndromeGregory G Schwartz, Michael Szarek, Esther Reijnders, et al.
Journal of the American College of Cardiology|March 12, 2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 TrialRobert F Storey, Dominick J Angiolillo, Marc P Bonaca, et al.
American Heart Journal|December 5, 2009
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working groupSunil V Rao, John Eikelboom, Ph Gabriel Steg, et al.
Circulation. Cardiovascular Interventions|February 24, 2022
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPIONBenjamin E Peterson, Robert A Harrington, Gregg W Stone, et al.
The New England Journal of Medicine|September 1, 2025
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral AnticoagulationGilles Lemesle, Romain Didier, Philippe Gabriel Steg, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
Indian Heart Journal|October 25, 2016
Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF surveyC Narasimhan, Jagmohan Singh Verma, A G Ravi Kishore, et al.
European Heart Journal|May 4, 2015
Effect of genetic variations on ticagrelor plasma levels and clinical outcomesChristoph Varenhorst, Niclas Eriksson, Åsa Johansson, et al.
Pageof 97

Showing results (601-610 of 962) with videos related to

Sort By:
Pageof 97
Journal of the American Heart Association|October 30, 2018
Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH ModelLotte Kaasenbrood, Deepak L Bhatt, Jannick A N Dorresteijn, et al.
Journal of the American Heart Association|October 7, 2022
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical IllnessGary E Raskob, Walter Ageno, Gregory Albers, et al.
European Journal of Preventive Cardiology|February 8, 2025
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndromeGregory G Schwartz, Michael Szarek, Esther Reijnders, et al.
Journal of the American College of Cardiology|March 12, 2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 TrialRobert F Storey, Dominick J Angiolillo, Marc P Bonaca, et al.
American Heart Journal|December 5, 2009
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working groupSunil V Rao, John Eikelboom, Ph Gabriel Steg, et al.
Circulation. Cardiovascular Interventions|February 24, 2022
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPIONBenjamin E Peterson, Robert A Harrington, Gregg W Stone, et al.
The New England Journal of Medicine|September 1, 2025
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral AnticoagulationGilles Lemesle, Romain Didier, Philippe Gabriel Steg, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
Indian Heart Journal|October 25, 2016
Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF surveyC Narasimhan, Jagmohan Singh Verma, A G Ravi Kishore, et al.
European Heart Journal|May 4, 2015
Effect of genetic variations on ticagrelor plasma levels and clinical outcomesChristoph Varenhorst, Niclas Eriksson, Åsa Johansson, et al.
Pageof 97